Therapeutic area intelligence for Acute Ischemic Stroke with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Fujian Shengdi Pharmaceutical →

Assets

Phase →

Recent signals(3)

ClinicalJuly 20, 2026

Trial on Intra-Arterial Cooling Infusion in Acute Ischemic Stroke Initiated

A multicenter trial is evaluating the safety and efficacy of selective intra-arterial cooling infusion combined with EVT in acute ischemic stroke.

ClinicalJune 30, 2026

Phase II Trial of HRS-7450 Injection for Acute Ischemic Stroke Initiated by Fujian Shengdi

Fujian Shengdi Pharmaceutical has initiated Phase II clinical trial for HRS-7450 Injection targeting Acute Ischemic Stroke.

ClinicalJune 27, 2026

Study on NeuAngio-CT Impact on Acute Ischemic Stroke Intervention

This study evaluates the effectiveness of NeuAngio-CT equipped emergency stroke unit in reducing reperfusion time for acute ischemic stroke patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.